Recombinant Human IL-13RA1 Protein (C-6His)

Name: Recombinant Human IL-13RA1 Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0305NP
Availability: InStock

BL-0305NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Cytokines and growth factors, Interleukins and receptors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Interleukin-13 Receptor Subunit Alpha-1 is produced by our Mammalian expression system and the target gene encoding Gly22-Thr343 is expressed with a 6His tag at the C-terminus.
Accession	P78552
Synonym	Interleukin-13 receptor subunit alpha-1; IL-13 receptor subunit alpha-1; IL-13R subunit alpha-1; IL-13R-alpha-1; IL-13RA1; Cancer/testis antigen 19; CT19; CD213a1; IL13RA1; IL13R; IL13RA
Gene Background	Interleukin-13 receptor subunit alpha-1(IL13RA1) is a subunit of the interleukin 13 receptor. This subunit forms a receptor complex with IL4 receptor alpha, a subunit shared by IL13 and IL4 receptors. The human IL13-Rα1 was originally cloned based on sequence homology to the mouse IL13-Rα1, it share 76% aa sequence identity. Human The IL13-Rα1 cDNA encodes a 427 amino acid (aa) residue precursor protein with a putative 21 aa residue signal peptide, a 324 aa residue extracellular domain, a 23 aa residue transmembrane region and a 59 aa residue cytoplasmic tail. The extracellular domain of IL13-Rα1 is also closely related to that of IL13-Rα2. It binds with low affinity to interleukin-13(IL13). IL13RA1 serves as a primary IL13- binding subunit of the IL13 receptor, and may also be a component of IL4 receptors. This protein has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4.
Molecular Mass	37.7 KDa
Apmol Mass	55-65 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity.
Subcellular Location	Membrane; Single-pass type I membrane protein.
Protein Families	Type I cytokine receptor family, Type 5 subfamily
Database References	HGNC: 5974 OMIM: 300119 KEGG: hsa:3597 STRING: 9606.ENSP00000360730 UniGene: Hs.496646
Tissue Specificity	Ubiquitous. Highest levels in heart, liver, skeletal muscle and ovary; lowest levels in brain, lung and kidney. Also found in B-cells, T-cells and endothelial cells.

Gene Functions References

High IL13RA1 expression is associated with Invasive breast Cancer. PMID: 28634667
in humans and mice indicate, for the first time, a role of interleukin-13 receptor alpha1 in myocardial homeostasis and heart failure and suggests a new therapeutic target to treat heart disease. PMID: 28528324
sIL13ralpha1 as a circulating human protein with an unexpected role in glucose metabolism. PMID: 28874358
IL-13Ralpha1 has a protective role in bleomycin-induced pulmonary injury and repair. PMID: 26153764
required for induction of the alternative macrophage activation pathway by IL-13 but not by IL-4 PMID: 25766112
Results identified FAM120A in the IL13/IL13Ralpha2 signaling pathway as a key mediator of invasion and liver metastasis in colon cancer. PMID: 25896327
miR-143 regulation of IL-13-induced inflammatory cytokine and mucus production in nasal epithelial cells from allergic rhinitis patients probably partly depends on inhibition of IL13Ralpha1. PMID: 25529447
MiR-143 may be associated with allergic reaction in human mast cells via downregulation of IL13RA1. PMID: 23965966
In humans, IL-13Ralpha1 lies within the PARK12 locus of susceptibility to Parkinson's disease and may have a role in the pathogenesis of this neurodegenerative disease. PMID: 23169588
These results indicate that an inherited polymorphism of the IL-4R controls the ability of the human immune system to regulate the magnitude of IL-17 production PMID: 21294892
The IL-13R A(1) +1398 A/G polymorphism does not contribute to asthma or allergic rhinitis susceptibility. PMID: 21425907
IL-13Ralpha1 is expressed on human CD4(+) T(H)17 cells PMID: 21236478
Mutation and functional analysis in human malignant glioma cells PMID: 11939409
IL4RA and STAT6 are candidate genes for atopic disorders. 26 single-nucleotide polymorphisms (SNPs)and simple repeats are being reported spanning a total of 147kb in IL4RA and STAT6 genes of the Indian population PMID: 12522691
Allele frequency of IL13RA1 polymorphism was not associated with rapid decline of lung function in smokers. PMID: 12594065
Overexpression of IL-13Ralpha1 may play some role in pathogenesis of chronic stage of atopic dermatitis or psoriasis. PMID: 14527737
Bronchial submucosal mast cell IL-13 receptor alpha 1 expression is higher in asthmatics than normal controls. PMID: 16918506
IL-13Ralpha1 polymorphism was associated with higher total IgE in children with atopic asthma PMID: 17006604
the IL13RA1 subunit gene -281T>G and 1365A>G polymorphisms do not contribute to asthma susceptibility or severity, although the IL13RA1 subunit gene locus might be involved in the control of immunoglobulin E production PMID: 17392323
concomitant expression of IL-13Ralpha1 and IL-13Ralpha2 may be associated with the pathogenesis of idiopathic interstitial pneumonia. PMID: 19654941

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.